AREDS data available
This article was originally published in The Tan Sheet
Executive Summary
Data collected for more than 10 years during the National Institutes of Health-sponsored Age-Related Eye Disease Study is available to researchers, the National Eye Institute announces Nov. 10. Researchers can apply for access to the complete medical history records or access public AREDS study descriptions and documents. The latest AREDS results showed antioxidants and zinc as therapeutic for age-related macular degeneration (1"The Tan Sheet" Jan. 21, 2008, p. 14). The NEI has completed enrollment for AREDS II (2"The Tan Sheet" Nov. 3, 2008, p. 19)
You may also be interested in...
SupplySide West In Brief
AREDS II rolling: Enrollment is complete and the second iteration of the National Eye Institute's Age-Related Eye Diseases Study is under way, according to Paul S. Bernstein, a researcher and professor of ophthalmology and visual sciences at the University of Utah School of Medicine's John A. Moran Eye Center. At the SupplySide West trade show in Las Vegas Oct. 22, Bernstein said through 2013, AREDS II will follow 4,000 patients between the ages of 50 and 85 with high risk for age-related macular degeneration at 100 U.S. sites. He explained that the antioxidant formulation for the first AREDS was "based on the best science of the 1980s" and omitted lutein and zeaxanthin, but the AREDS II formulation includes those carotenoids at levels about five times greater than a typical American diet. The revised formulation also lowers the original zinc and beta-carotene levels due to concerns about urinary tract problems and lung cancer, respectively. The AREDS results, released in 2001, showed high-dose antioxidant vitamins and minerals reduce the risk of advanced AMD progression by 25 percent (1"The Tan Sheet" Jan. 21, 2008, p. 14)
Antioxidants Continue To Show Benefits In AREDS Follow-Up
The latest follow-up to the Age-Related Eye Diseases Study continues to show "beneficial effects" of antioxidants and zinc as therapy for age-related macular degeneration, according to Emily Y. Chew, the study chairwoman at the National Eye Institute
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.